From the Departments of Pharmacology (D.J.B., C.A.F., G.L.W.) Neuroscience (C.D.P., K.F.K., S.L., C.A.F., G.L.W.) Pharmaceutics (C.A.F.) Dermatology (G.L.W.) Medicinal Chemistry (E.A., P.S.P.), University of Minnesota, Minneapolis, Minnesota.
Anesthesiology. 2019 Sep;131(3):649-663. doi: 10.1097/ALN.0000000000002840.
The long-term use of opioids for analgesia carries significant risk for tolerance, addiction, and diversion. These adverse effects are largely mediated by μ-opioid receptors in the central nervous system. Based on the authors' previous observation that morphine and δ-opioid receptor agonists synergize in spinal cord in a protein kinase Cε-dependent manner, they predicted that this μ-opioid receptor-δ-opioid receptor synergy would take place in the central terminals of nociceptive afferent fibers and generalize to their peripheral terminals. Therefore, the authors hypothesized that loperamide, a highly efficacious μ-opioid receptor agonist that is excluded from the central nervous system, and oxymorphindole, a δ-opioid receptor agonist that was shown to synergize with morphine spinally, would synergistically reverse complete Freund's adjuvant-induced hyperalgesia.
Using the Hargreaves assay for thermal nociception, the von Frey assay for mechanical nociception and the complete Freund's adjuvant-induced model of inflammatory pain, we tested the antinociceptive and antihyperalgesic effect of loperamide, oxymorphindole, or the loperamide-oxymorphindole combination. Animals (Institute for Cancer Research [ICR] CD1 strain mice; n = 511) received drug by systemic injection, intraplantar injection to the injured paw, or a transdermal solution on the injured paw. Dose-response curves for each route of administration and each nociceptive test were generated, and analgesic synergy was assessed by isobolographic analysis.
In naïve animals, the loperamide-oxymorphindole combination ED50 value was 10 times lower than the theoretical additive ED50 value whether given systemically or locally. In inflamed animals, the combination was 150 times more potent systemically, and 84 times more potent locally. All combinations showed statistically significant synergy when compared to the theoretical additive values, as verified by isobolographic analysis. The antihyperalgesia was ablated by a peripherally-restricted opioid antagonist.
From these data we conclude that the loperamide-oxymorphindole combination synergistically reverses complete Freund's adjuvant-induced inflammatory hyperalgesia. The authors also conclude that this interaction is mediated by opioid receptors located in the peripheral nervous system.
长期使用阿片类药物进行镇痛会导致耐受、成瘾和滥用等显著风险。这些不良反应主要是由中枢神经系统中的μ-阿片受体介导的。基于作者之前观察到吗啡和 δ-阿片受体激动剂在脊髓中以蛋白激酶 Cε 依赖性方式协同作用,他们预测这种 μ-阿片受体-δ-阿片受体协同作用将发生在伤害性传入纤维的中枢末端,并扩展到其外周末端。因此,作者假设洛哌丁胺,一种高效的 μ-阿片受体激动剂,被排除在中枢神经系统之外,和奥甲啡,一种与吗啡在脊髓中协同作用的 δ-阿片受体激动剂,将协同逆转完全弗氏佐剂诱导的痛觉过敏。
使用热伤害感受的 Hargreaves 测定法、机械伤害感受的 von Frey 测定法和完全弗氏佐剂诱导的炎症性疼痛模型,作者测试了洛哌丁胺、奥甲啡或洛哌丁胺-奥甲啡组合的镇痛和抗痛觉过敏作用。动物(ICR CD1 品系小鼠;n=511)通过系统注射、受伤足内注射或受伤足的透皮溶液给予药物。生成了每种给药途径和每种伤害感受测试的剂量-反应曲线,并通过等比图形分析评估镇痛协同作用。
在未受伤的动物中,洛哌丁胺-奥甲啡组合的 ED50 值比理论相加 ED50 值低 10 倍,无论系统给药还是局部给药。在炎症动物中,组合系统给药的效力高 150 倍,局部给药的效力高 84 倍。与理论相加值相比,所有组合均显示出统计学上显著的协同作用,这通过等比图形分析得到了验证。外周限制的阿片受体拮抗剂可消除抗痛觉过敏作用。
从这些数据中,作者得出结论,洛哌丁胺-奥甲啡组合协同逆转完全弗氏佐剂诱导的炎症性痛觉过敏。作者还得出结论,这种相互作用是由位于外周神经系统中的阿片受体介导的。